Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 78.60% | -32.51% | -43.90% | -62.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 78.60% | -32.51% | -43.90% | -62.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 78.60% | -32.51% | -43.90% | -62.33% |
| SG&A Expenses | 4.77% | 17.17% | 15.16% | 3.20% | -17.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.91% | 28.24% | -14.48% | 13.16% | 12.11% |
| Operating Income | -61.56% | -25.61% | 11.96% | -26.18% | -34.71% |
| Income Before Tax | -28.24% | -28.45% | 10.52% | -139.35% | 78.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.24% | -28.45% | 10.52% | -139.35% | 78.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.24% | -28.45% | 10.52% | -139.35% | 78.20% |
| EBIT | -61.56% | -25.61% | 11.96% | -26.18% | -34.71% |
| EBITDA | -62.47% | -26.21% | 11.94% | -27.20% | -35.70% |
| EPS Basic | 2.83% | -0.33% | 23.17% | -130.88% | 89.77% |
| Normalized Basic EPS | -19.88% | -1.14% | 25.40% | -121.82% | 91.66% |
| EPS Diluted | 2.83% | -0.33% | 23.17% | -130.88% | 89.77% |
| Normalized Diluted EPS | -19.88% | -1.14% | 25.40% | -121.82% | 91.66% |
| Average Basic Shares Outstanding | 31.92% | 27.99% | 16.46% | 27.44% | 113.06% |
| Average Diluted Shares Outstanding | 31.92% | 27.99% | 16.46% | 27.44% | 113.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |